Laekna, Inc. (HK:2105) has released an update.
Laekna, Inc. has reported significant advancements in their drug development programs, including the commencement of a Phase I clinical trial for their obesity treatment, LAE102, ahead of schedule, and the initiation of a Phase III trial for LAE002 in combination with fulvestrant for breast cancer. Both treatments have shown promise, with LAE002 demonstrating a well-tolerated safety profile and efficacy in prior studies, and the company plans to present further clinical data at upcoming medical conferences.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.
